Observation of a higher JAK2 V617F homozygous mutated clone in polycythemia vera compared to essential thrombocythemia

Abstract

Single-tube bi-directional allele specific amplification (SB-ASA) and real-time quantitative polymerase chain reaction (RQ-PCR) assays were developed and performed for JAK2V617F detection on 40 polycythemia vera (PV) samples, 31 essential thrombocythemia (ET) samples, 40 acute leukemia samples, and 40 healthy control samples. Differences between detect limitations of the two assays and their influence on the mutation detection rate were analyzed. The results showed that in some samples, the JAK2V617F burden was as low as nearly 1%, and thus more JAK2V617F-positive samples were detected by RQ-PCR than by SB-ASA assay due to the former higher detect limitation. Mutation allele ratios in PV and ET samples and their relevance to biological characteristics were also analyzed. The results showed that the mutation allele ratio was 0.436 ± 0.261 in PV, higher than the 0.216 ± 0.207 in ET; percentage of certainly homozygous mutation carriers in PV was 40.54%, higher than the 10% in ET. However, statistical analysis showed no relevance between mutation allele burden and sex or age. Our result shows that the pathogenesis of PV and ET may be related to the mutation allele burden of JAK2V617F.

References

1. James C, Ugo V, Le Couédic J P, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval J L, Constantinescu S N, Casadevall N, Vainchenker W . A unique clonal JAK2 mutation leading to constitutivesignalling causes polycythaemia vera. Nature, 2005, 434(7037): 1144–1148. doi:10.1038/nature03546
2. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz S B, Zhao Z J . Identification of an Acquired JAK2 Mutationin Polycythemia Vera. J Biol Chem, 2005, 280(24): 22788–22792. doi:10.1074/jbc.C500138200
3. Baxter E J, Scott L M, Campbell P J, East C, Fourouclas N, Swanton S, Vassiliou G S, Bench A J, Boyd E M, Curtin N, Scott M A, Erber W N, Green A R . Acquired mutation of the tyrosine kinase JAK2 in humanmyeloproliferative disorders. Lancet, 2005, 365(9464): 1054–1061
4. Lacout C, Pisani D F, Tulliez M, Gachelin F M, Vainchenker W, Villeval J L . JAK2V617F expression in murine hematopoietic cells leadsto MPD mimicking human PV with secondary myelofibrosis. Blood, 2006, 108(5): 1652–1660. doi:10.1182/blood‐2006‐02‐002030
5. Wernig G, Mercher T, Okabe R, Levine R L, Lee B H, Gilliland D G . Expression of Jak2V617F causes a polycythemia vera-like disease withassociated myelofibrosis in a murine bone marrow transplant model. Blood, 2006, 107(11): 4274–4281. doi:10.1182/blood‐2005‐12‐4824
6. Finazzi G, Barbui T . How I treat patients withpolycythemia vera. Blood, 2007, 109(12): 5104–5111. doi:10.1182/blood‐2006‐12‐038968
7. Vannucchi A M, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P . A quantitative assay forJAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR andcapillary electrophoresis. Leukemia, 2006, 20(6): 1055–1060. doi:10.1038/sj.leu.2404209
8. Dupont S, Massé A, James C, Teyssandier I, Lécluse Y, Larbret F, Ugo V, Saulnier P, Koscielny S, Le Couédic J P, Casadevall N, Vainchenker W, Delhommeau F . The JAK2 617V > F mutationtriggers erythropoietin hypersensitivity and terminal erythroid amplificationin primary cells from patients with polycythemia vera. Blood, 2007, 110(3): 1013–1021. doi:10.1182/blood‐2006‐10‐054940
9. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi A M . Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 2005, 19(10): 1847–1849. doi:10.1038/sj.leu.2403902
10. Pemmaraju N, Moliterno A R, Williams D M, Rogers O, Spivak J L . The quantitative JAK2 V617F neutrophilallele burden does not correlate with thrombotic risk in essentialthrombocytosis. Leukemia, 2007, 21(10): 2210–2212. doi:10.1038/sj.leu.2404755
11. Vardiman J W, Harris N L, Brunning R D . The World Health Organization (WHO) classification ofthe myeloid neoplasms. Blood, 2002, 100(7): 2292–2302. doi:10.1182/blood‐2002‐04‐1199
12. Levine R L, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, Gilliland D G, Busque L . X-inactivation–basedclonality analysis and quantitative JAK2V617F assessment reveal astrong association between clonality and JAK2V617F in PV but not ET/MMM,and identifies a subset of JAK2V617F-negative ET andMMM patients withclonal hematopoiesis. Blood. 2006, 107(10): 4139–4141. doi:10.1182/blood‐2005‐09‐3900
13. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupré N, Skoda R C, Hermouet S . The JAK2-V617F mutation is frequently present at diagnosisin patients with essential thrombocythemia and polycythemia vera. Blood, 2006, 108(6): 1865–1867. doi:10.1182/blood‐2006‐01‐013540
14. McClure R, Mai M, Lasho T . Validation of two clinically useful assays for evaluationof JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia, 2006, 20(1): 68–171. doi:10.1038/sj.leu.2403999
16. Kralovics R, Passamonti F, Buser A S, Teo S S, Tiedt R, Passweg J R, Tichelli A, Cazzola M, Skoda R C . A gain-of-functionmutation of JAK2 in myeloproliferative disorders. N Engl J Med, 2005, 352(17): 1779–1790. doi:10.1056/NEJMoa051113
17. Murugesan G, Aboudola S, Szpurka H, Verbic M A, Maciejewski J P, Tubbs R R, Hsi E D . Identificationof the JAK2 V617F mutation in chronic myeloproliferative disordersusing FRET probes and melting curve analysis. Am J Clin Pathol, 2006, 125(4): 625–633
18. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T . Risk of thrombosis in patientswith essential thrombocythemia and polycythemia vera according toJAK2 V617F mutation status. Haematologica, 2007, 92(1): 135–136. doi:10.3324/haematol.10634
19. Frohling S, Lipka D B, Kayser S, Scholl C, Schlenk R F, Dohner H, Gilliland D G, Levine R L, Dohner K . Rare occurrenceof the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood, 2006, 107(3): 1242–1243. doi:10.1182/blood‐2005‐09‐3644
20. Steensma D P, Dewald G W, Lasho T L, Powell H L, McClure R F, Levine R L, Gilliland D G, Tefferi A . The JAK2 V617F activating tyrosine kinase mutation isan infrequent event in both “atypical” myeloproliferativedisorders and myelodysplastic syndromes. Blood, 2005, 106(4): 1207–1209. doi:10.1182/blood‐2005‐03‐1183
21. Patel R K, Lea N C, Heneghan M A, Westwood N B, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, Gaken J, Wendon J, Heaton N D, Mufti G J . Prevalence of the activating JAK2 tyrosinekinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology, 2006, 130(7): 2031–2038. doi:10.1053/j.gastro.2006.04.008
22. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell'Era A, Bucciarelli P, Mannucci P M . Role of the JAK2 mutation in the diagnosis of chronicmyeloproliferative disorders in splanchnic vein thrombosis. Hepatology, 2006, 44(6): 1528–1534. doi:10.1002/hep.21435
23. Scott L M, Scott M A, Campbell P J, Green A R . Progenitorshomozygous for the V617F mutation occur in most patients with polycythemiavera, but not essential thrombocythemia. Blood, 2006, 108(7): 2435–2437. doi:10.1182/blood‐2006‐04‐018259
24. Campbell P J, Scott L M, Buck G, Wheatley K, East C L, Marsden J T, Duffy A, Boyd E M, Bench A J, Scott M A, Vassiliou G S, Milligan D W, Smith S R, Erber W N, Bareford D, Wilkins B S, Reilly J T, Harrison C N, Green A R . Definition of subtypes ofessential thrombocythaemia and relation to polycythaemia vera basedon JAK2 V617F mutation status: a prospective study. Lancet, 2005, 366(9501): 1945–1953. doi:10.1016/S0140‐6736(05)67785‐9
25. Tefferi A, Pardanani A . Evaluation of “increased”hemoglobin in the JAK2 mutations era: a diagnostic algorithm basedon genetic tests. Mayo Clin Proc, 2007, 82(5): 599–604
26. James C, Delhommeau F, Marzac C, Teyssandier I, Couédic J P, Giraudier S, Roy L, Saulnier P, Lacroix L, Maury S, Tulliez M, Vainchenker W, Ugo V, Casadevall N . Detection of JAK2 V617F as a first intention diagnostictest for erythrocytosis. Leukemia, 2006, 20(2): 350–353. doi:10.1038/sj.leu.2404069